How does volume status affect BNP and troponin levels as markers of cardiovascular status in peritoneal dialysis?

Congestive Heart Failure

Volumn 15, Issue 5, 2009, Pages 240-244

  Garg, Rajeev ^a   Singh, Avneet ^b   Khaja, Azam ^a   Martin, Alpert ^a   Aggarwal, Kul ^a  

^a University of Missouri   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; TROPONIN; TROPONIN I; TROPONIN T; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE CORONARY SYNDROME; CARDIOVASCULAR FUNCTION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; FLUID RETENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE OVERLOAD; HUMAN; KIDNEY FUNCTION; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; UREMIA; BLOOD; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; STATISTICS;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERITONEAL DIALYSIS; PROGNOSIS; STATISTICS AS TOPIC; STROKE VOLUME; TROPONIN; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 70349764767     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00094.x     Document Type: Review

References (47)

1. London GM, Pannier B, Guerin AP. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001, 12:2759-2767.
2. Venkatesan J, Henrich WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Am J Kidney Dis 1997, 17:257-269.
3. Asci G, Ozkahya M, Duman S. Volume control associated with better cardiac function in long term peritoneal dialysis patients. Perit Dial Int 2006, 26:85-88.
4. Ishibe S, Peixoto AJ. Methods of assessment of volume status and intercompartmental fluid shifts in hemodialysis patients: implications in clinical practice. Semin Dial 2004, 17:37-43.
5. Woodrow G. Can we improve fluid balance and cardiovascular outcomes in peritoneal dialysis patients?. Perit Dial Int 2006, 26:49-52.
6. Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol 1999, 10:392-403.
7. Naganuma T, Sugumura K, Wada S. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002, 22:437-444.
8. Goto T, Takase H, Toriyama T. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 2002, 92:610-15.
9. Fagugli RM, Palumbo B, Ricciardi D. Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract 2003, 95:c60-c66.
10. Lee SW, Song JH, Kim GA. Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patients. Am J Kidney Dis 2003, 41:1257-1266.
11. Yasue H, Yoshimura M, Sumida H. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994, 90:195-203.
12. Hunt PJ, Yandle TG, Nicholls MG. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995, 214:1175-1183.
13. Pemberton CJ, Johnson ML, Yandle TG. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000, 36:355-359.
14. Yandle TG, Richards AM, Gilbert A. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993, 76:832-838.
15. Maisel AS, Krishnaswamy P, Nowak RM. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
16. Mueller C, Scholer A, Laule-Kilian K. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004, 350:647-654.
17. Davis M, Espiner E, Richards G. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994, 343:440-444.
18. Maisel AS, McCord J, Nowak RM. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003, 41:2010-2017.
19. Berger R, Huelsman M, Strecker K. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 105:2392-2397.
20. Cheng V, Kazanagra R, Garcia A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001, 37:386-391.
21. Koglin J, Pehlivanli S, Schwaiblmair M. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001, 38:1934-1941.
22. Yu CM, Sanderson JE. Plasma brain natriuretic peptide: an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999, 1:59-65.
23. Kazanegra R, Cheng V, Garcia A. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001, 7:21-29.
24. Buckley MG, Sethi D, Markandu ND. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci 1992, 83:437-444.
25. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 1998, 95:519-529.
26. Obineche EN, Pathan JY, Fisher S. Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis. Kidney Int 2006, 69(1):152-156.
27. Zoccali C, Mallamaci F, Benedetto FA. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001, 12(7):1508-1515.
28. Mallamaci F, Zoccali C, Tripepi G. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001, 59(4):1559-1566.
29. Taskapan MC, Ulutas O, Aksoy Y. Brain natriuretic peptide and its relationship to left ventricular hypertrophy in patients on peritoneal dialysis or hemodialysis less than 3 years. Ren Fail 2006, 28(2):133-139.
30. Nakatani T, Naganuma T, Masuda C. Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis. Int J Mol Med 2002, 10(4):457-461.
31. Wang AY, Lam CW, Yu CM. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007, 18(1):321-330.
32. Nishikimi T, Futoo Y, Tamano K. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 2001, 37:1201-1208.
33. Granja CA, Tailor PT, Gorban-Brennan N. Brain natriuretic peptide and impedance cardiography to assess volume status in peritoneal dialysis patients. Adv Perit Dial 2007, 23:155-160.
34. Lee JA, Kim DH, Yoo SJ. Association between serum n-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2006, 26(3):360-365.
35. Bavbek N, Akay H, Altay M. Serum BNP concentration and left ventricular mass in CAPD and automated peritoneal dialysis patients. Perit Dial Int 2007, 27(6):663-668.
36. Heeschen C, Hamm CW, Bruemmer J. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000, 35:1535-1542.
37. Frankel WL, Herold DA, Ziegler TW. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996, 106:118-123.
38. Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. Clin Chem 1998, 44:1410-1416.
39. Dierkes J, Domrose U, Westphal S. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000, 102:1964-1969.
40. Mallamaci F, Zoccali C, Parlongo S. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002, 40:68-75.
41. deFilippi C, Wasserman S, Rosanio S. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003, 290:353-359.
42. Duman D, Tokay S, Toprak A. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2005, 20:962-967.
43. Apple FS, Murakami MM, Pearce LA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002, 106:2941-2945.
44. Ooi D, Zimmerman D, Graham J. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 2001, 47:412-417.
45. Lowbeer C, Gutierrez A, Gustafsson SA. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. Nephrol Dial Transplant 2002, 17:2178-2183.
46. Havekes B, van Manen JG, Krediet RT. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2006, 47:823-829.
47. Wang AY, Lam CW, Wang M. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. Clin Chem 2007, 53:882-889.